

Amendments to the Claims

Claims 1-113 (cancelled)

Claim 114 (currently amended): An isolated peptide less than 15 amino acids in length comprising a peptide consisting of the sequence ~~an oligopeptide selected from the group consisting of:~~

~~—————HSFPIPLY (SEQ ID NO:92)~~
~~—————ALGTTCYA (SEQ ID NO:6853)~~
VLAKELKFV (SEQ ID NO:6827)
~~—————ILLWQPIPV (SEQ ID NO:6831)~~
~~—————IMYSAHDTTV (SEQ ID NO:6836) and~~
~~—————LLFFWLDRSV (SEQ ID NO:6825).~~

Claims 115-120 (cancelled)

Claim 121 (previously added): The peptide of claim 114 which is 11 amino acids in length.

Claim 122 (previously added): The peptide of claim 114 which is 10 amino acids in length.

Claim 123 (previously added): The peptide of claim 114 which is 9 amino acids in

length.

Claim 124 (currently amended): The peptide of claim 114, which is fused to a T helper peptide.

Claim 125 (previously added): The peptide of claim 114, which is fused to spacer or linker amino acids.

Claim 126 (previously added): The peptide of claim 114, which is fused to a carrier.

Claim 127 (previously added): The peptide of claim 114, which is linked to a lipid.

Claim 128 (previously added): A fusion protein comprising the peptide of claim 114.

Claim 129 (previously added): A homopolymer of the peptide of claim 114.

Claim 130 (previously amended): A heteropolymer of the peptide of claim 114 and different peptides.

Claim 131 (previously added): A composition comprising the peptide of claim 114 and a carrier.

Claim 132 (cancelled)

Claim 133 (previously added): A composition comprising the peptide of claim 114 and a liposome.

Claim 134 (currently amended): A composition comprising the peptide of claim 114 ~~117~~ and a pharmaceutically acceptable carrier.

Claim 135 (currently amended): A composition comprising the peptide of claim 114, and one or more ~~second~~other peptides.

Claim 136 (previously added): The composition of claim 135, wherein said peptides form a fusion protein.

Claim 137 (previously added): The composition of claim 135, which comprises a carrier.

Claim 138 (cancelled)

Claim 139 (previously added): The composition of claim 135, wherein said peptides are fused by spacer or linker amino acids.

Claim 140 (previously added) The composition of claim 135, which comprises a pharmaceutically acceptable carrier.

Claims 141-214 (cancelled)

Claim 215 (currently amended): The peptide of claim 124 ~~214~~, wherein the T helper peptide is a PADRE® ~~universal T helper cell~~ pan-DR-binding epitope.

Claims 216-229 (cancelled)

Claim 230 (new): The peptide of claim 215, wherein the pan-DR-binding epitope comprises the amino acid sequence of SEQ ID NO:6698.